Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02307240 · ClinicalTrials.gov registry record · Phase 1

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

A Phase 1 study of Solid Tumors and Triple Negative Breast Cancer, sponsored by Curis.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
4
Study locations

NCT02307240 is a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer that has completed, run by Curis. The registered enrollment target is 43 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02307240, a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer, has completed, sponsored by Curis.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
4
Study locations

Study Summary

This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

Conditions Studied

Solid Tumors Triple Negative Breast Cancer High-grade Serous Ovarian Cancer NUT Midline Carcinoma

Interventions

  • DRUG CUDC-907

Study Locations (4)

California

  • UCSF School of Medicine - San Francisco

Florida

  • Florida Cancer Specialists - Sarasota

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2014-11
Est. Completion 2019-05-31
Phase Phase 1

Sponsor

Curis

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02307240

The ClinicalTrials.gov registry entry for NCT02307240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (85% lower). The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CUDC-907 is the first listed.

NCT02307240 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02307240 about?

NCT02307240 is a clinical study titled "Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors". This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

What is the current status of trial NCT02307240?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2014-11. Estimated completion is 2019-05-31.

What conditions does trial NCT02307240 study?

This clinical trial studies the following conditions: Solid Tumors, Triple Negative Breast Cancer, High-grade Serous Ovarian Cancer, NUT Midline Carcinoma.

What interventions are being tested in trial NCT02307240?

The interventions under investigation include: CUDC-907 (DRUG).

Who is sponsoring clinical trial NCT02307240?

This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02307240 being conducted?

This trial has 4 study locations across California, Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Triple Negative Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.